Stay updated with breaking news from Development Unit Oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Not intended for US-, Canada- and UK-based media First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative
Not intended for UK-based media First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential of xevinapant
New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology Clinical trials in locally advanced head and neck cancer and advanced bladder
38-month median follow-up data from the Phase III JAVELIN Bladder 100 trial demonstrated prolonged median OS of 23.8 months with BAVENCIO plus best supportive care (BSC) in the first-line maintenance